{
    "code": "52028047",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52028047",
    "time": "2022-03-11 05:19:00",
    "許可證字號": "衛部藥輸字第028047號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "115\/03\/25",
    "發證\/登錄日期": "110\/03\/25",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA05202804702",
    "中文品名": "克瘤康膠囊100毫克",
    "英文品名": "Calquence Capsules 100mg",
    "適應症": "1.先前曾接受至少一種治療的被套細胞淋巴瘤 (Mantle Cell Lymphoma, MCL) 成年病人。\r\n2.慢性淋巴球性白血病 (Chronic Lymphocytic Leukemia, CLL) 或小淋巴球性淋巴瘤 (Small Lymphocytic Lymphoma, SLL) 成年病人。",
    "劑型": "130膠囊劑",
    "包裝": "4-1000粒ALU-ALU鋁箔盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "新成分",
    "監視期限": "115\/03\/25",
    "主成分略述": "acalabrutinib",
    "限制項目": "02輸　入 1S須執行確認性療效臨床試驗",
    "申請商名稱": "1434901100  臺灣阿斯特捷利康股份有限公司",
    "申請商地址": "台北市大安區敦化南路二段207號21樓",
    "主製造廠": [
        {
            "": "SWEDEN",
            "製程": ""
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013008800",
            "成分名稱": "acalabrutinib",
            "含量描述": "",
            "含量": "100.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "克瘤康膠囊100毫克中文核定仿單-Calquence Capsules 100mg-110-04-14.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028047&Seq=001&Type=9"
        },
        {
            "title": "克瘤康膠囊100毫克-鋁箔核定本-PS18883-110-04-14.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028047&Seq=002&Type=8"
        },
        {
            "title": "克瘤康膠囊100毫克-外盒核定本-PS18738-110-04-14.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028047&Seq=001&Type=8"
        }
    ]
}